Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of AbbVie's ABBV-400?
ABBV-400 is a monoclonal antibody conjugated commercialized by AbbVie, with a leading Phase II program in Metastatic Colorectal Cancer. According...
ABBV-400 by AbbVie for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
ABBV-400 is under clinical development by AbbVie and currently in Phase I for Squamous Non-Small Cell Lung Cancer. According to...
ABBV-400 by AbbVie for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
ABBV-400 is under clinical development by AbbVie and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction. According to...
ABBV-400 by AbbVie for Renal Cell Carcinoma: Likelihood of Approval
ABBV-400 is under clinical development by AbbVie and currently in Phase I for Renal Cell Carcinoma. According to GlobalData, Phase...
ABBV-400 by AbbVie for Solid Tumor: Likelihood of Approval
ABBV-400 is under clinical development by AbbVie and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...
ABBV-400 by AbbVie for Gastric Cancer: Likelihood of Approval
ABBV-400 is under clinical development by AbbVie and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I...
ABBV-400 by AbbVie for Colorectal Cancer: Likelihood of Approval
ABBV-400 is under clinical development by AbbVie and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I...
Risk adjusted net present value: What is the current valuation of AbbVie's ABBV-400?
ABBV-400 is a monoclonal antibody conjugated commercialized by AbbVie, with a leading Phase II program in Metastatic Colorectal Cancer. According...
ABBV-400 by AbbVie for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
ABBV-400 is under clinical development by AbbVie and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC)....